secwatch.observer — SEC 8-K summary
======================================

Issuer:     PAVmed Inc. (PAVM)
CIK:        0001624326
Form:       8-K
Filed at:   2023-04-03T23:59:59+00:00
Accession:  0001493152-23-010544
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PAVmed Subsidiary Lucid Diagnostics Announces Medicare Coverage Determination for Esophageal Cancer Testing
--------------------------------------------------------------------------------

- MolDX Program published Future Effective Local Coverage Determination L39256 on March 30, 2023
- Coverage applies to molecular testing for esophageal precancer and cancer in Medicare beneficiaries
- Determination becomes effective May 14, 2023
- Lucid Diagnostics is a majority-owned subsidiary of PAVmed Inc.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1624326/000149315223010544/0001493152-23-010544-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1624326/000149315223010544/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-010544

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer